Baird Maintains Neutral on Elevance Health, Raises Price Target to $393
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice TargetHot
Baird analyst Michael Ha maintains Elevance Health (NYSE:ELV) with a Neutral and raises the price target from $331 to $393.
Baird analyst Michael Ha maintains Elevance Health (NYSE:ELV) with a Neutral and raises the price target from $331 to $393.